Italian Journal of Anatomy and Embryology - contenuto non piu disponibile

Read full text
Authors: Corinne Portioli, Marco Pedroni, Donatella Benati, Stefano Dusi, Marta Donini, Raffaella Mariotti, Roberta Bonafede, Luigi Perbellini, Marzia Cerpelloni, Adolfo Speghini, Marina Bentivoglio
Cited by: 0
References: 2

Abstract

Among the wide range of nanoparticles (NPs) studied for diagnostic and therapeutic applications lanthanide-doped nanosystems have raised special interest [1]. Their very small dimension (10 nm) and upconversion emission property have increased the range of their applications from contrast agent probes in bioimaging to drug delivery systems [2,3]. Here, the cytotoxicity of rare earth (Yb and Er)-doped CaF2 and SrF2 NPs has been investigated both in vitro and in vivo. In vitro studies have been conducted in a motoneuron cell line as model of neuronal interaction, and in a line of human dendritic cells which play a key role in the immune response. In the motoneuron cell line, a weak response was observed at early time points while the cell viability showed an increment, except for the highest concentration of lanthanide- doped NPs. The levels of cytokines released from human dendritic cells were low and dose-dependent. The NP biodistribution was investigated after a single peripheral administration in mice. Aggregates of NPs were shown, with different techniques, mostly in peripheral organs (spleen and liver) after one day. A limited penetration of both CaF2 and SrF2 NPs was seen in the brain parenchyma, associated with a mild astrocytic activation. Since the present in vitro findings indicate that lanthanide- doped NPs are safe, and the in vivo data show that they can enter the brain parenchyma crossing the blood-brain barrier, these NPs may represent promising tools for diagnostic and therapeutical applications.

Fields of Study & Subjects

Nanoplatforms for cancer theranostics Luminescence Properties of Advanced Materials Carbon and Quantum Dots Applications

Publication details

Volume
120
Issue
1
Pages
185–185
Publication date
8 July 2026
Language
EN